

REMARKS

The present invention relates to previously unknown biological roles of Nogo-B.

Claims 39-45 and 49-59 are currently pending because the available records on public PAIR indicate that the previously filed Amendment in response to the Final Office Action has been entered. Claims 39-41, 44, 45, and 49-54 have been withdrawn from consideration as being drawn to a non-elected invention.

Claims 39-55 have been canceled herein without disclaimer or prejudice to the inclusion of the subject matter contained therein in any later filed continuation or divisional application(s) as set forth below. Claims 56 and 59 have been amended as discussed more fully below.

The present Supplemental Amendment serves to, among other things, address issues raised by the Examiner in the Telephonic Interview that took place on July 29, 2009 with Applicants' representative, the undersigned, as discussed more fully below.

Applicants Statement of the Interview dated July 29, 2009

Applicants appreciate the time taken by the Examiner during the telephone interview that took place on July 29, 2009, with Applicants' representative, Quang Nguyen. During the telephone interview, it was agreed that Applicants would file a Supplemental Amendment to address the Examiner's concerns.

Claims 39-55 have been canceled.

Claim 56 has been amended to recite a method for promoting endothelial cell adhesion, spreading and migration in treating a condition or disease characterized by pathological vascular remodeling in a subject in need thereof. Support for this amendment is found throughout the specification, for example, in lines 3-18 of page 31. No new matter has been added.

Claim 59 has been amended to recite "blood vessel injury". Support for this amendment is found at least in lines 19-31 of page 31. Therefore no new matter has been added by way of this amendment.

Claim 57 has been reviewed with respect to the Markush group. Applicants respectfully submit that the diseases recited in claim 57 are diseases

associated with vascular remodeling. For example, the specification beginning on line 28, page 28, discloses that Nogo-B is a mediator of vascular remodeling. In addition, the specification on line 31, page 29, discloses the role of Nogo-B as a therapeutic target for restenosis, stenosis after transplant vasculopathy, atherosclerosis, myocardial infarction, cerebrovascular infarction in hypertensive patients. Thus, Applicants submit that the specification supports hypertension, restenosis, transplant vasculopathy, arteriosclerosis, pulmonary hypertension, myocardial infarction and cerebrovascular infarction as a condition or disease characterized by pathological vascular remodeling.

With respect to ischemia, support is found in Example 11.

With respect to asthma, the specification discloses that asthma is a condition characterized by vascular remodeling. In an effort to appease the Examiner, provided herewith is a copy of Avdalovic et al., 2006 Am J Respir Crit Care Med 174: 1069-1076. The reference indicates that vascular remodeling is associated with asthma. Thus, Applicants submit that claim 57 is in condition for allowance.

Conclusion

Applicants respectfully submit that the pending claims, are fully supported in the specification as filed, and are therefore in condition for allowance. Favorable examination and allowance of the claims is hereby requested.

Respectfully submitted,

WILLIAM C. SESSA ET AL.,

August 6, 2009
(Date)

By:


QUANG D. NGUYEN, Ph.D.
Registration No. 52,066
DRINKER, BIDDLE & REATH, LLP
One Logan Square
18th and Cherry Streets
Philadelphia, PA 19103-6996
Telephone: (215) 988-2700
Direct Dial: (215) 988-2720
Facsimile: (215) 988-2757
E-Mail: Quang.Nguyen@dbr.com
Agent for Applicants

Enclosure: Avdalovic et al., 2006 Am J Respir Crit Care Med 174: 1069-1076